Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) is developing cancer vaccines designed to treat a broad range of solid tumor cancers more efficiently and cost-effectively than current treatments, and without the side effects of chemotherapy drugs. The company has a broad platform technology for DCVax dendritic cell-based vaccines, and its lead product, DCVax-L, is currently in a 348-patient phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. For more information, visit the company’s website atwww.nwbio.com.